Kresladi granted accelerated approval for LAD-I

What this means

Kresladi is a gene therapy that treats severe leukocyte adhesion deficiency-I (LAD-I), a rare immune disorder where white blood cells can't fight infections properly. FDA granted accelerated approval for Kresladi in pediatric patients based on early evidence suggesting it may help. This decision gives children with this life-threatening condition access to a potentially life-changing treatment while further studies confirm its long-term benefits.